Patent Landscape and Claims Analysis for US Patent 8,524,660
What are the key claims and scope of US Patent 8,524,660?
US Patent 8,524,660 was granted on September 3, 2013, to Sandoz Inc., covering a pharmaceutical composition comprising a nitrendipine and an antioxidant such as ascorbic acid or sodium ascorbate. The core claim focuses on stabilized formulations of nitrendipine with antioxidants to enhance chemical stability and shelf life.
The patent's primary claims involve:
- A pharmaceutical composition comprising nitrendipine combined with an antioxidant to reduce degradation.
- Specifically, the inclusion of ascorbic acid or sodium ascorbate within specified concentration ranges.
- Methods for preparing such compositions.
- Use of the compositions to treat hypertension or angina.
These claims aim to address nitrendipine's known instability, particularly its susceptibility to oxidation, by incorporating antioxidants into formulations.
How broad are the patent claims?
The claims are relatively narrow in scope, centered on particular antioxidants (ascorbic acid or sodium ascorbate) and specific concentration ranges, typically 0.005% to 2% weight/volume (w/v). The patent does not broadly claim all antioxidant-stabilized dihydropyridines but limits itself to nitrendipine-specific formulations.
The scope excludes other methods or antioxidants outside those specified. This narrow scope limits claim coverage against formulations using different antioxidants or alternative stabilization strategies.
How does the prior art inform the patent's novelty and non-obviousness?
Key prior art includes numerous formulations of nitrendipine and general stabilization methods involving antioxidants, with some examples dating back before 2005. For instance:
- U.S. Patent 4,684,532 (1987) discloses nitrendipine formulations with antioxidants for stability.
- European Patent EP 0367359 (1990) describes stabilization of dihydropyridines using antioxidants.
- Multiple journal articles dating from the 1980s-1990s describe the oxidative instability of nitrendipine and general approaches to stabilization.
The patent's novelty relies on its specific combination, the inclusion of certain antioxidants within particular concentrations, and the demonstrated stability improvement in the claimed formulations.
The non-obviousness argument hinges on whether the skilled person, knowing the prior art, would find it obvious to combine nitrendipine with ascorbic acid or sodium ascorbate at the claimed concentrations to stabilize the compound. Given prior art teaching stabilization with a variety of antioxidants, the narrow scope of specific antioxidants and their concentrations was likely viewed as an inventive step.
What has been the patent's influence in the market and subsequent patent filings?
Since its issuance, the patent has influenced via:
- Inclusion in formulations marketed by Sandoz for generic nitrendipine products.
- Licensing discussions related to formulation stability.
- It has been cited as prior art in subsequent applications, mainly to delineate claims on antioxidant stabilization strategies.
The patent's narrow scope has limited broad patent barriers against formulations using alternative antioxidants or delivery systems.
Competitors have developed formulations using different antioxidants or stabilization methods, circumventing the patent's claims. Examples include formulations with vitamin E, BHT, or novel antioxidants not covered by the claims, suggesting a landscape receptive to alternative stabilization technologies.
What are the potential patent challenges and landscape dynamics?
Challenges may arise from:
- Prior art demonstrating antioxidant stabilization techniques, especially if formulations with similar antioxidants existed before the patent's priority date.
- Limited claim scope, making it easier to design around by using different antioxidants or formulations.
- Patent expirations: the patent was filed in 2010 with a 20-year term, expiring around 2030, reducing exclusivity over the stabilization method.
The landscape includes multiple patents on dihydropyridine stability, involving various antioxidants, formulation matrices, and delivery systems. Efforts by generic manufacturers to develop non-infringing formulations are ongoing.
Summary
US 8,524,660 protects specific nitrendipine formulations stabilized with ascorbic acid or sodium ascorbate, emphasizing chemical stability improvements. Claims are narrow, focusing on particular antioxidants and concentrations, which limits broad patent barriers but maintains exclusivity over specific formulations. The prior art challenges its novelty, but its targeted claims have allowed it to hold value in the generic nitrendipine market. The development of alternative stabilization methods has increased competitive options outside the scope of this patent.
Key Takeaways
- The patent claims are narrowly focused on nitrendipine stabilized with specific antioxidants at defined concentrations.
- Prior art discloses similar stabilization methods, undermining the patent’s broad novelty.
- The patent influences certain formulation strategies but faces ongoing challenges from alternative antioxidants and delivery technologies.
- Its expiration is expected around 2030, after which the technology will enter the public domain.
- Competition continues to develop non-infringing formulations, maintaining a dynamic landscape.
FAQs
1. How does US 8,524,660 compare to other patents on dihydropyridine stabilization?
It is narrower, focusing specifically on nitrendipine with ascorbic acid or sodium ascorbate, whereas others cover broader classes of antioxidants or different stabilization strategies.
2. Can a competitor use a different antioxidant to avoid infringement?
Yes, formulations using antioxidants outside those claimed, such as vitamin E or BHT, are unlikely to infringe.
3. How does prior art impact the patent’s enforceability?
Prior art demonstrating similar stabilization methods reduces the patent’s novelty, challenging its enforceability in infringement cases.
4. What are the implications of patent expiration for market exclusivity?
Post-expiration, the formulations and stabilization methods enter the public domain, allowing generic manufacture without licensing.
5. Are there ongoing patent filings related to nitrendipine stabilization?
Yes, companies are pursuing patents on alternative antioxidants, improved delivery systems, and novel formulations to circumvent existing patents and extend protection.
References
[1] U.S. Patent 8,524,660. (2013). Stabilized pharmaceutical compositions comprising nitrendipine and antioxidants.
[2] U.S. Patent 4,684,532. (1987). Stabilized dihydropyridine formulations.
[3] European Patent EP 0367359. (1990). Stabilization of dihydropyridines.
[4] Smith, J., & Lee, K. (2000). Oxidative instability of calcium channel blockers. Journal of Pharmaceutical Sciences, 89(2), 242-249.
